Now is a crucial time for the gene therapy field, as the ripple effects of pioneering approvals in both the US and Europe are being felt globally, setting new benchmarks and posing unexpected questions. Gene Therapy for Rare Disorders Europe is the uniquely focused conference that will bring the leaders in this field together to discuss the critical factors involved in driving commercial success for gene therapies in the complex European landscape. Bringing together leading experts from innovative biotechs, large pharma, payers, investors and academics, this conference will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.
Gene Therapy for Rare Disorders Europe is the only conference solely dedicated to realising the commercial potential of gene therapies in the rare disease space. With a new wave of gene therapies on the cusp of approval in Europe and investment at an all-time high, Gene Therapy for Rare Disorders Europe will leverage the experience from the companies at the leading edge, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy,
safety and commercial viability. Rather than early stage basic science, this meeting is devoted to addressing the latest clinical, manufacturing, regulatory and commercialization challenges facing this rapidly evolving field.
Across three days, this conference will unite over 100 leading experts from innovative biotechs, large pharma, academia and key service provider companies.
Some of the featured speakers include:
- Jim Thomson, Senior Manager, Market Access & Gene Therapy, Pfizer
- Samantha Parker, SVP & Chief Patient Access Officer, Lysogene
- Marcus Droege, Global Head, RWE & Evidence, AveXis, a Novartis Company